Hwail Pharmaceutical Co (061250) Fair Value & Analysis
Healthcare · KR · Market cap 66.0B KRW
Fair value as of: Jul 6, 2026
From 7 valuation models · updated yesterday
Fair value updated Jul 6, 2026 — revised from 110,592 KRW to 19,477 KRW (−82.4%) since Jun 24, 2026. Share price +6.6% over the past month.
Price vs Fair Value (12 months)
12‑month range 7,410 KRW – 13,720 KRW · fair‑value band 15,825 KRW – 23,130 KRW · the 8,520 KRW price screens below the 19,477 KRW fair value. As of Jul 6, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Hwail Pharmaceutical Co (061250) currently trades at 8,520 KRW, while our model-based Fair Value estimate is 19,477 KRW — implying the stock looks roughly 128.6% undervalued today. We read business quality at 52/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Over the trailing twelve months, Hwail Pharmaceutical Co generated revenue of 108B KRW at a net margin of 1.8%. Revenue declined 11.6% year over year. It earns a return on equity of 1.9%. Fundamentals as of Jul 6, 2026
Our scenario range runs from 15,825 KRW (bear case) to 23,130 KRW (bull case); at 8,520 KRW, the current price sits below that range. The share trades about 38% below its 52-week high and 18% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -48% fair-value upside — at 129%, 061250 screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 6, 2026. TTM = trailing twelve months.
About the company
Hwail Pharmaceutical Co.,Ltd. develops pharmaceutical raw materials in South Korea. It provides raw drug products, finished drug products, and functional health food raw material business. The company was founded in 1974 and is headquartered in Seongnam-si, South Korea.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Hwail Pharmaceutical Co reported revenue of 101B KRW in FY2025 versus 107B KRW in FY2021, a compound −1.5%/yr. Reported net income was −233M KRW in FY2025.
Is 061250 fairly valued? → Check now
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 6, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,863 | ₹1,039 | -44% |
| Zoetis Inc Z1TS34 | R$24.45 | R$6.33 | -74% |
| Hansoh Pharmaceutical Group 3692 | HK$29.58 | HK$18.75 | -37% |
| Divi's Laboratories Limited DIVISLAB | ₹6,788 | ₹2,035 | -70% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,421 | ₹1,504 | -66% |
| Cipla Limited CIPLA | ₹1,433 | ₹1,035 | -28% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,098 | ₹507.31 | -54% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,272 | ₹720.15 | -43% |
| PharmaEssentia Corporation 6446 | 937.00 TWD | 322.35 TWD | -66% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Hwail Pharmaceutical Co (061250) undervalued?
What is the fair value of 061250?
What is the quality score of 061250?
What is the revenue of Hwail Pharmaceutical Co (061250)?
What is the net profit margin of 061250?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.